Arizona Clinic's DEA License Revoked After Ghosting Hearings
Published Date: 7/16/2025
Notice
Summary
Benson Sergiles, P.A., a medical practice in Arizona, lost its DEA registration because it no longer has the state permission to handle controlled substances. Despite multiple attempts, the DEA couldn’t reach them for a hearing, so the registration was revoked by default. This means Benson Sergiles can’t legally manage controlled drugs anymore, effective immediately, impacting their business operations.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for Arizona Practice
Benson Sergiles, P.A., a medical practice in Peoria, Arizona, had its DEA Certificate of Registration No. MB7529261 revoked. The revocation means the practice cannot legally possess, prescribe, distribute, or dispense controlled substances in Arizona as of August 15, 2025.
Pending Renewal and New Applications Denied
The DEA Order also denies any pending applications from Benson Sergiles, P.A. to renew or modify its DEA registration and denies any other pending application for additional registration in Arizona. These denials are included in the Order effective August 15, 2025.
15-Day Window to Seek Reconsideration
The Order states Benson Sergiles, P.A. may file a motion for reconsideration of the Agency's factual findings within fifteen calendar days of the date of the Order. Any such motion and responses must be filed and served by email to the other party and to the DEA Office of the Administrator.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-13314, Formations of, Acquisitions by, and Mergers of Bank Holding Companies
Bank companies want to merge or buy other banks, and the Federal Reserve is checking their plans to keep things safe and fair. If you care, you can send your thoughts by August 15, 2025. These moves could change who controls some banks and might affect local banking options and money flow.
Next: 2025-13316, Osric Malone Prioleau, N.P.; Decision And Order
Osric Malone Prioleau, a nurse practitioner from West Virginia, lost his DEA registration because he no longer has state permission to handle controlled substances. He didn’t ask for a hearing, so the DEA officially revoked his registration as of early 2025. This means he can’t legally prescribe or manage controlled drugs anymore, effective immediately.